ARS Pharmaceuticals (SPRY) Share-based Compensation (2020 - 2026)

ARS Pharmaceuticals (SPRY) has 7 years of Share-based Compensation data on file, last reported at $65.0 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation rose 1126.88% year-over-year to $65.0 million; the trailing twelve-month figure through Mar 2026 stood at $65.0 million (up 502.63% YoY), and the FY2025 full-year result was $42.4 million, up 3.16% from the prior year.
• Share-based Compensation advanced to $65.0 million in Q1 2026, from -$530000.0 in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $65.0 million in Q1 2026 to a low of -$530000.0 in Q4 2025.
• A 5-year average of $5.8 million and a median of $2.2 million in 2023 frame the typical range for Share-based Compensation.
• Peak annual rise in Share-based Compensation reached 1953.49% in 2025, while the deepest fall reached 112.43% in 2025.
• Tracing SPRY's Share-based Compensation over 5 years: stood at $4.8 million in 2022, then tumbled by 52.17% to $2.3 million in 2023, then surged by 87.14% to $4.3 million in 2024, then sank by 112.43% to -$530000.0 in 2025, then jumped by 12364.15% to $65.0 million in 2026.
• Business Quant data shows SPRY's Share-based Compensation at $65.0 million in Q1 2026, -$530000.0 in Q4 2025, and $5.7 million in Q3 2025.